State of Alaska Department of Revenue Buys 10,025 Shares of United Therapeutics Co. (NASDAQ:UTHR)

State of Alaska Department of Revenue grew its stake in shares of United Therapeutics Co. (NASDAQ:UTHRFree Report) by 153.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,557 shares of the biotechnology company’s stock after buying an additional 10,025 shares during the period. State of Alaska Department of Revenue’s holdings in United Therapeutics were worth $3,802,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Rise Advisors LLC bought a new stake in United Therapeutics in the first quarter worth $32,000. GAMMA Investing LLC purchased a new position in United Therapeutics during the fourth quarter worth $43,000. Janiczek Wealth Management LLC boosted its stake in United Therapeutics by 21.1% during the first quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after buying an additional 84 shares during the period. Blue Trust Inc. boosted its stake in United Therapeutics by 10.0% during the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock worth $114,000 after buying an additional 46 shares during the period. Finally, Quadrant Capital Group LLC boosted its stake in United Therapeutics by 31.2% during the fourth quarter. Quadrant Capital Group LLC now owns 581 shares of the biotechnology company’s stock worth $128,000 after buying an additional 138 shares during the period. Institutional investors own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 13,800 shares of United Therapeutics stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $237.27, for a total value of $3,274,326.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at $30,845.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other United Therapeutics news, Director Nilda Mesa sold 266 shares of the business’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $318.58, for a total value of $84,742.28. Following the completion of the transaction, the director now directly owns 5,107 shares in the company, valued at $1,626,988.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 13,800 shares of the business’s stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $237.27, for a total transaction of $3,274,326.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,845.10. The disclosure for this sale can be found here. Insiders sold 112,544 shares of company stock worth $29,811,740 over the last three months. 12.50% of the stock is owned by corporate insiders.

United Therapeutics Stock Performance

UTHR stock opened at $314.56 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The business has a 50-day moving average price of $282.72 and a 200 day moving average price of $246.29. The company has a market capitalization of $13.95 billion, a P/E ratio of 14.87, a PEG ratio of 1.37 and a beta of 0.55. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $325.00.

United Therapeutics (NASDAQ:UTHRGet Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating the consensus estimate of $5.63 by $0.54. The firm had revenue of $677.70 million during the quarter, compared to the consensus estimate of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The firm’s quarterly revenue was up 33.7% on a year-over-year basis. During the same period in the previous year, the company posted $4.86 earnings per share. As a group, equities research analysts forecast that United Therapeutics Co. will post 24.73 EPS for the current fiscal year.

Analyst Ratings Changes

UTHR has been the subject of several recent analyst reports. The Goldman Sachs Group lifted their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. HC Wainwright reaffirmed a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, May 2nd. Oppenheimer lifted their price objective on shares of United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. JPMorgan Chase & Co. boosted their target price on shares of United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research note on Tuesday, May 21st. Finally, StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 20th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $312.22.

Read Our Latest Report on UTHR

United Therapeutics Company Profile

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Further Reading

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.